Elmar Schnee
Elmar Schnee
Chairman
VIEW BIO
Elmar Schnee
Elmar Schnee
Chairman

Born 1959. Board member since 2019.

Education: Master’s degree in marketing and management from IMD.

Board Committees: Chairman of the Remuneration Committee.

Experience: Elmar Schnee was previously CEO of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as General Partner and member of the Executive Board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.

Other current assignments: Chairman of the board of directors of Santhera Pharmaceutical, ProCom Rx SA, Moleac Pte Lts and Noorik Biopharmaceuticals AG as well a member of the board of directors of Jazz Pharmaceuticals, Stallergenes Greer and Damian Pharma AG.

Holdings in the Company: Elmar Schnee holds 23,236 share awards in board LTIP 2019.

Independent in relation to the Company and its management and in relation to major shareholders.

Thomas Eklund
Thomas Eklund
Non-executive Director
VIEW BIO
Thomas Eklund
Thomas Eklund
Non-executive Director

Born 1967. Board member since 2017.

Education: MBA from Stockholm School of Economics.

Board Committees: Chairman of the Audit Committee.

Experience: Thomas Eklund has extensive experience in the pharmaceutical and medtech industry as well as the financial sector. He has held different executive positions, including CEO and Head of Europe at Investor Growth Capital AB. His previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment AB and Vice President at Handelsbanken Markets.

Other current assignments: Chairman of the Board of Directors of Itrim Holding AB, Moberg Pharma AB (publ) and Sedana Medical AB (publ). Member of the Board of Directors of Biotage AB, Boule Diagnostics AB, Eklund konsulting AB, Excillum Aktiebolag, Memira Holding AB, Neoventa Medical AB, Rodebjer Form AB, SciBase Holding AB (publ), Surgical Science Sweden AB, Swedencare AB (publ) and TEDCAP AB.

Holdings in the company: Thomas Eklund holds 445 warrants of Class C* and 8,449 share awards in board LTIP 2019.

Independent in relation to the Company and its management and in relation to major shareholders.

Hilde Furberg
Hilde Furberg
Non-executive Director
VIEW BIO
Hilde Furberg
Hilde Furberg
Non-executive Director

Born 1958. Board member since 2014.

Education: Master of Science in Engineering from Oslo University, Norway.

Board Committees: Member of the Audit Committee.

Experience: Hilde Furberg is an independent consultant and professional Board member. She has extensive experience of leadership from her 35 years in sales, marketing, strategy and management in Pharma / Biotech. Her experience is in various fields of rare diseases, which she gained working in small companies and large global corporations. Hilde has worked in companies such as Genzyme and Baxter, she was most recently SVP and General Manger / European Head of Rare Diseases at Sanofi Genzyme. In addition to working for Genzyme / Sanofi Genzyme, Hilde has since 2005 worked as non-executive director and Board member of Probi, Pronova, Clavis, Bergenbio and Algeta.

Other current assignments: She is currently an industrial advisor to Investinor and Board member of Tappin, PCI Biotech and Chairman of Blueprint Genetic.

Holdings in the company: Hilde Furberg holds 15,250 shares in the company, 118 warrants of Class B* and 8,449 share awards in board LTIP 2019.

Independent in relation to the Company and its management and in relation to major shareholders.

Lennart Hansson
Lennart Hansson
Non-executive Director
VIEW BIO
Lennart Hansson
Lennart Hansson
Non-executive Director

Born 1956. Board member since 2009.

Education: PhD in Genetics from the University of Umeå.

Experience: Lennart Hansson has broad experience from leading positions within pharmaceutical develop¬ment and business development in both biotech and pharma companies such as KabiGen AB, Symbicom AB, AstraZeneca, Biovitrum AB and as CEO of Arexis AB. Lennart was responsible for Industrifonden’s life science operations between 2008– 2016. He has worked on more than 30 company boards and is also the co-founder of two pharmaceutical development companies.

Other current assignments: Chairman of the Board of Directors of Sixera Pharma AB and Ignitus AB. Member of the Board of Directors of Cinclus AB, InDex Pharmaceuticals Holding AB (publ), and Medivir AB (publ).

Holdings in the company: Lennart Hansson holds 9,000 shares in the company and 8,449 share awards in board LTIP 2019.

Independent in relation to the Company and its management and in relation to major shareholders.

Bengt Julander
Bengt Julander
Non-executive Director
VIEW BIO
Bengt Julander
Bengt Julander
Non-executive Director

Born 1953. Board member since 2004.

Education: Master of Pharmacy from Uppsala University.

Experience: Bengt Julander is a pharmacist and has worked in the pharmaceutical industry since 1978. He is the CEO of Linc AB, which invests in life sciences, including in Calliditas. Since 1990, Bengt Julander has been primarily active as an investor in, and a Board member of, pharmaceutical development companies. He has experience of developing and commercializing pharmaceutical products.

Other current assignments: Chairman of the Board of Directors of Knil AB. Member of the Board of Directors of Linc AB, Medivir Aktie¬bolag, Stille AB, Nefecon AB, Swevet AB, ProEquo AB, Sedana Medical AB (publ), Busulipo AB, nWise AB, Swevet Holding AB, Pharmalink Nordic AB and Cronhamn Invest AB. Deputy member of the board of Kv Eldstaden i Bromma AB, Algarvefastigheter AB, Eriksbergskliniken Gam AB, Linc Global AB, Linc International AB, Korkyl Holding AB, Eriksbergskliniken AB and Linc Trade AB.

Holdings in the company: Bengt Julander holds (directly and indirectly through company) 4,836,108 shares in the company.

Independent in relation to the Company and its senior management, but not in relation to major shareholders.

Diane Parks
Diane Parks
Non-executive Director
VIEW BIO
Diane Parks
Diane Parks
Non-executive Director

Born 1952. Board member since 2019.

Education: Master’s degree from Kansas State University and an MBA from Georgia State University.

Board Committees: Member of the Remuneration Committee.

Experience: Diane Parks is a senior executive with deep sales and marketing experience from the US, where she has held positions such as Head of US Commercial for Kite Pharma, VP of Sales for Amgen and Head of Global Marketing at Pharmacyclics.

Other current assignments: –

Holdings in the Company: Diane Parks holds 8,449 share awards in board LTIP 2019.

Independent in relation to the Company and its management and in relation to major shareholders.

Shareholding in the Company as of May 31, 2019.

* For more information on the incentive programs, see section “Governance – Remuneration”.